世界卫生组织召集专家小组，就刚果民主共和国和乌干达报告的Bundibugyo病毒引发的埃博拉疫情提出了治疗和疫苗建议[1]。专家组推荐三种治疗候选药物，分别是单克隆抗体MBP134、Maftivimab®以及瑞德西韦，其中单克隆抗体与瑞德西韦的联合疗法也被提议采用[1]。针对暴露后预防，专家组建议采用口服抗病毒药物obeldesirvir[1]。
在疫苗方面，专家组确定了两种最有前景的候选产品[1]。其中，由国际艾滋病疫苗倡议组织（IAVI）开发的rVSV Bundibugyo疫苗需要7至9个月的准备时间才能进入临床试验[1]；由牛津大学与印度血清研究所联合开发的ChAdOx1 Bundibugyo疫苗可能在2至3个月内用于临床试验[1]。已获批的Ervebo疫苗不适用于Bundibugyo病毒疾病的预防，仅建议在精心设计的研究环境中使用[1]。
目前所有推荐的产品均无针对Bundibugyo病毒疾病的特定批准，专家组建议这些候选治疗药物和疫苗仅在临床试验中使用[1]。
The World Health Organization has assembled a panel of experts to evaluate candidate therapeutic and vaccine options for Ebola disease caused by the Bundibugyo virus, which has been reported in the Democratic Republic of the Congo and Uganda.[1] The expert group recommended three candidate drugs for treatment: the monoclonal antibodies MBP134 and Maftivimab®, along with remdesivir, which can be used in combination.[1] For post-exposure prevention, the panel advised the oral antiviral medication obeldesirvir.[1]
On the vaccine front, experts identified two leading candidates as the most promising options.[1] The rVSV Bundibugyo vaccine, developed by IAVI, would require seven to nine months of preparation before entering clinical trials, while the ChAdOx1 Bundibugyo vaccine, developed by the University of Oxford and the Serum Institute of India, could potentially be available for clinical trials within two to three months.[1] The previously approved Ervebo vaccine is not suitable for Bundibugyo virus disease prevention and is recommended only in carefully designed research settings.[1] At present, all candidate products lack specific approval for this disease and are recommended for use solely within clinical trial frameworks.[1]